AT First Diagnostic's market success has come from a broad acceptance of the performance of its products by clinical laboratory professionals. All of First Diagnostic's products are based on the same unique flow-through membrane technology, which relies on highly specific antigen-antibody reactions allowing for the detection of disease-specific markers in clinical specimens. In our rapid tests, a special membrane is coated with disease-specific antigens or antibodies to capture the corresponding marker in the test sample, thus allowing for the detection of the disease. The simple testing procedure involves placing a drop of the test sample on the coated test membrane and allowing it to flow through the membrane. If the sample contains the target antibodies or antigens, they are captured on the test membrane and result in a highly specific antigen-antibody complex. The test result is visualized at a colored line through a reaction with a proprietary detection agent and can be interpreted immediately.

AT First Diagnostic deploys its unique micro flow-through testing platform; including a single buffer solution for preparation and performance of the test and unique colorimetric agent, which allows for a visual interpretation of test results. The testing procedure is completed within minutes. Precision pipetting, sample manipulation or specialized equipment is not required to perform any of First Diagnostic's rapid tests, making it an invaluable diagnostic resource in laboratories that are space and time limited.

Multiple Applications
AT First Diagnostic's market-proven, flow-through membrane technology platform can be used quickly and efficiently to develop tests for many diseases, from smallpox to emerging diseases such as avian influenza. First Diagnostic develops disease-specific rapid tests based on its proprietary technology, making all test procedures similarly simple and user-friendly. As a result, First Diagnostic is able to develop and market reliable, high-quality tests for other diseases quickly, and ensure ready acceptance and use by medical laboratories.

The Rapid Test Principle
Its test method for the immune chromatography method is the combination of the immunochemistry and the chromatography method, and it is applied with a specific immune reactivity of an antibody to an antigen, coloring characteristic and mobility of a colloidal gold particle, and a molecule's movement by a capillary phenomenon of a porous membrane. The immune chromatography method is integrated the specimen dilution in the existing multi-step immune measurement method, cleaning, and the coloring process through the reaction between an enzyme complex and a substrate into one system so that a test can be executed fast and conveniently in one-step. And its test result can be decided without any specific equipment for many advantages of easiness, economic feasibility and fast interpretation of a test result.

Manufacture Technology of Gold Colloid
AT First Diagnostic has its own manufacture technology of Gold colloid, which is the core material of the rapid immunochromatographic assay. Therefore, we can supply you excellent products stably.

Antibody Conjugation Technnology
There are two core technologies required for developing a rapid immunochromatographic test kit that uses Gold colloid and an antigen (antibody). The first one is the technology to conjugate various types of antigens (antibodies) to Gold colloid and the second is to fix an antigen (antibody) on a nitrocellulose membrane. These technologies are closely concerned with a ultra-high speed test kit's peculiarity and sensitivity, that is, the product's quality so that these are treated considerably accurately, and these can be regarded as the most important technologies for the product. AT First Diagnostic LLC., has devoted itself to apply its vast experiences and various professional knowledge on its rapid test kit development, and to develop a faster and more accurate test kit.

We expect to be highly competitive in the market due to our scientists' ability to process reagents in conjunction with their expertise in producing high quality end-products in various diagnostic applications for genetic diseases, cancer prognosis, individual identifications, infectious disease identifications, and others.